Kafkasli A.Buhur A.Burak F.Taskin O.2024-08-042024-08-0419971300-0438https://hdl.handle.net/11616/91128Objective: To evaluate the effect of Flavinoid fraction; 450 mg Diasmin + 50 mg Hesperidin (DH), a venotrophic drug, in the treatment of the primary dysmenorrhea. Study Design: Thirty women, presenting with moderate (6 of 30, 20%) or severe (24 of 30, 80%) primary dysmenorrhea, were randomly divided into 2 groups. Each group received either DH tid or placebo for three months immediately after the onset of the menstrual flow and then each group was switched to the other regimen for the following three months. Ten point visual analogue scale was used to measure the pain of the patients. Statistical analysis was carried out by using student's t test, and chi square-test. Results: Pain scores were similiar in the placebo and the DH treated groups before treatment (7.5 ± 0.7 and 8.1 ± 0.2 respectively). Pain scores began to decrease one-hour following the DH administration and reduced to the lowest point at the third hour (from 5.5 ± 0.9 to 3.4 ± 0.9, p < 0.05). Satisfactory pain relief was detected in 90% of the patients. Meanwhile, pain scores in the placebo group did not change (7.8 ± 0.1 versus 7.6 ± 0.2, p > 0.05). The severity of the pain returned to pretreatment levels when the patients were switched to placebo. Conclusion: DH may be an effective drug for the treatment of primary dysmenorrhea in patients who can not use nonsteroidal anti-inflammatory drugs.trinfo:eu-repo/semantics/closedAccessdiasminhesperidineprimary dysmenorrheaArticle631061102-s2.0-0030860458N/A